Back
 Health  Vol.9 No.4 , April 2017
Prevalence of Hypertension and Associated Factors in Patients Living with HIV Followed at the Ambulatory Treatment Center (CTA) of Fann National University Hospital in Dakar
Abstract:
Introduction: The efficacy of antiretroviral therapy in people living with HIV (PLHIV) has been associated with an important increase in metabolic disorders, such as hypertension (HTA). This work allowed us to estimate the prevalence of hypertension in PLHIV and to describe associated factors. Methods: A retrospective, descriptive and analytical study was carried out based on the records of people living with HIV followed at the Ambulatory Treatment Center (CTA), from January 1st 1998 to 31st, December 2014. The WHO criteria were used to diagnose hypertension. Data entry was performed using ESOPE software and data analysis was done using Epi Info software version 3.5.3. A multiple logistic regression was used to identify the risk factors associated with hypertension. Results: During the study period, 3624 patients followed at CTA were included of which 1184 patients (32.7%) had hypertension. The average age was 47. 3 years ±10.5 years, with a sex ratio of 0.7. The most common opportunistic infections at diagnosis were tuberculosis (14.9%) and oral candidiasis (15.3%). The HIV infection was advanced (stage 3 or 4 of WHO classification) for 39% of cases. Overweight and obesity was found in 19.1%. Only 17.6% were treated by protease inhibitors. Higher average age (OR:1,05; IC [1.04 - 1.05], p = 0.000001), higher average BMI (OR:5,3; IC [3.3 - 8.5], p = 0.00001), WHO clinical stage I-II (OR:1,4; IC [1.2 - 1.6], p = 0.00003), and ARV treatment (OR:2,5; IC [1.7 - 3.7], p = 0.000001) are associated with the occurrence of hypertension. Conclusion: The prevalence of hypertension was high among PLHIV and associated factors were: advanced age, high BMI, WHO clinical stages I and II and antiretroviral therapy. Hence, the interest of a systematic screening of hypertension and others cardiovascular risk factors particularly in patients under ARV antiretroviral therapy.
Cite this paper: Gueye, N. , Ka, D. , Tall, A. , Ndiaye, K. , Ndiaye, A. , Cisse, V. , Guindo, A. , Badiane, N. , Diop, S. , Manga, N. , Ndour, C. and Seydi, M. (2017) Prevalence of Hypertension and Associated Factors in Patients Living with HIV Followed at the Ambulatory Treatment Center (CTA) of Fann National University Hospital in Dakar. Health, 9, 727-737. doi: 10.4236/health.2017.94052.
References

[1]   ONUSIDA (2012) Le point sur l’épidémie. Rapport ONUSIDA sur l’épidémie mondiale de SIDA en 2012.
http://www.unaids.org/en/media/unai

[2]   Kramoh, E.K., N’Goran, Y.N.K., Akie-Trabousi, E., et al. (2011) Hypertension Management in an Outpatient Clinic at the Institute of Cardiology of Abidjan (Ivory Coast). Archives of Cardiovascular Diseases, 104, 558-564.
https://doi.org/10.1016/j.acvd.2011.08.002

[3]   Yayehd, K., Damorou, F., Akalkpo, R., et al. (2011) Prévalence de l’hypertension artérielle et description de ses facteurs de risque à Lomé (Togo): Résultats d’un dépistage réalisé dans la population générale en mai 2011. Annales de Cardiologie et d’Angéiologie.

[4]   Bernardino De La Serna, J.I., Zamora, F.X., Montes, M.L., et al. (2008) Hipertension arterial, infeccion por el virus de la inmunodeficiencia humana y tratamiento antiretrovirico de gran actividad. Enfermedades Infecciosas y Microbiología Clínica, 28, 32-37.
https://doi.org/10.1016/j.eimc.2008.07.005

[5]   Bergersen, B.M., Sandvik, L., Dunlop, O., et al. (2003) Prevalence of Hypertension in HIV-Positive Patients on Highly Active Antiretroviral Therapy (HAART) Compared with HAART Naive and HIV-Negative Controls: Results from a Nowegian Study of 721 Patients. European Journal of Clinical Microbiology & Infectious Diseases, 22, 731-736.
https://doi.org/10.1007/s10096-003-1034-z

[6]   Leye, A.W.F. (2012) Les facteurs de risque cardiovasculaires chez les patients vivant avec le VIH: Etude multicentrique à propos de 133 cas. Thèse Méd, Dakar, No. 91.

[7]   Chironi, G., Simon, A. and Vittecoq, D. (2004) Le risque cardiovasculaire au cours des traitements antirétroviraux. Médecine Thérapeutique, 10, 120-128.

[8]   Gallet, B., Chedin, P. and Pulik, M. (1999) Complications cardiovasculaires chez les patients infectés par le VIH: Les antiprotéases sontelle en cause? Sang Thrombose Vaisseaux, 11, 511-516.

[9]   Saves, M., Chene, G., Ducimetiere, P., et al. (2003) Risk Factors for Coronary Heart Disease in Patients Treated for Human Immunodeficiency Virus Infection Compared with the General Population. Clinical Infectious Diseases, 37, 292-298.
https://doi.org/10.1086/375844

[10]   Capeau, J., Bouteloup, V., Katlama, C., et al. (2012) Ten-Year Diabetes Incidence in 1046 HIV-Infected Patients Started on a Combination Antiretroviral Treatment. AIDS, 26, 303-314.
https://doi.org/10.1097/QAD.0b013e32834e8776

[11]   Friis-Moller, N., Reiss, P., Sabin, C.A., et al. (2007) Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. The New England Journal of Medicine, 356, 1723-1735.
https://doi.org/10.1056/NEJMoa062744

[12]   Mbaye, M.N., Niang, K., Sarr, A., Mbaye, A., Diedhiou, D., Ndao, M.D. et al. (2011) Aspects épidémiologiques du diabète au Sénégal: Résultats d’une enquête sur les facteurs de risque cardiovasculaire dans la ville de Saint-Louis. Médecine des Maladies Métaboliques, 5, 659-664.
https://doi.org/10.1016/S1957-2557(11)70343-1

[13]   Diouf, A., Cournil, A., Ba-Fall, K., Ngom-Gueye, N.F., Eymard-Duvernay, S., Ndiaye, I., et al. (2012) Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors. International Scholarly Research Network, 2012, Article ID: 621565.

[14]   Coulibaly, A.M. (2013) Mortalité sous trithérapie ARV: Prévalence et facteurs associés chez les patients infectés par le VIH sous traitement ARV de 1ère ligne suivi au CTA du CHUN de Fann Thèse Méd, Dakar, No. 1.

[15]   Hewitt, R.G., Thompson IV, W.M., Chu, A., et al. (2001) Indinavir not Nelfinavir, Is Associated with Systemic Hypertension When Compared to No Protease Inhibitor Therapy. The International AIDS Conference, Chicago, Abstract No. 658.

 
 
Top